Having problems viewing this email? View in Browser       

Image

The HFEA's monthly newsletter for clinic staff

September 2025

There’s still time to complete our Choose a Fertility Clinic (CaFC) focused consultation

As mentioned in our June, July and August editions of Clinic Focus, we are seeking views on the main profile page statistics shown on each licensed clinic’s Choose a Fertility Clinic profile page.

 

We are running this consultation to get views on which statistics are most helpful for the public and best represent fertility treatment today, to support us in deciding what statistics should be shown on a clinic’s main profile page to give a broad overview of that clinic’s success rates.

 

This focused consultation is open to both patients and professionals and closes next week at 5pm on Tuesday 30 September 2025. It should take around 10 minutes to complete. If you haven’t already, then please complete this and also pass it on to colleagues in the sector.

 

Click here to complete the consultation. 

 

Reminder: Using calcium ionophore in fertility treatment

The use of calcium ionophore for artificial oocyte activation (AOA) is an HFEA authorised process under “processing gametes”. Calcium ionophore is only authorised for AOA. Clinics using calcium ionophore for AOA should follow the relevant professional body (ARCS/BFS) guidance. The HFEA’s Scientific and Clinical Advances Advisory Committee (SCAAC) summarised the guideline as follows:

  • AOA should not be used routinely with ICSI as its safety, in terms of the potential developmental consequences and birth outcomes, has yet to be established.
  • ICSI with AOA may be used where two previous routine ICSI cycle(s) have resulted in <30% or no fertilisation.
  • Where AOA is used, patients should be advised that safety, in terms of the potential developmental consequences and birth outcomes, has not been established.
  • Patients should be provided with safety data relating to the specific AOA technique used.

The SCAAC removed calcium ionophore for AOA from the HFEA treatment add-ons list in October 2023. This decision was taken on the basis that it should not be offered to the general fertility patient population, but only in limited circumstances as outlined in the ARCS/BFS guideline. The ESHRE (European) guidance takes a similar approach and only recommends calcium ionophore for AOA in limited circumstances.

 

The use of calcium ionophore for poor blastocyst or embryo development was also raised at the October 2023 SCAAC meeting. The SCAAC Deputy Chair, a member of the ARCS/BFS guideline committee, said guideline authors were aware of the research into other uses of calcium ionophore, but “wanted to take a cautious approach, not permitting the technique for other indications until further evidence is available."

 

For more information, please see SCAAC minutes October 2023. The SCAAC monitors new research and technological developments in fertility treatment on an ongoing basis. Any new evidence arising on the use of calcium ionophore in fertility treatment would be examined by the Committee.

 

Audit of conditions approved for PGT-M

The HFEA ensures that the list of conditions approved for PGT-M remains up to date and consistent with the statutory requirements set out under Schedule 2 of the HFE Act 2008 (as amended). The list is subject to periodic audits to review advances in treatment that would lessen the seriousness of any of the conditions previously approved for PGT-M.

 

We will be undertaking an audit of the list of conditions over the next 12 months. During this process we will be engaging with expert reviewers and key stakeholders. Any decisions to retain, amend or remove conditions from the list will be taken by the Statutory Approvals Committee (SAC). We will notify the sector of the audit’s outcomes, including any changes to the PGT-M list, via Clinic Focus.

 

Importance of submitting desk-based assessment (DBA) documents on time

As outlined in our Inspection strategy a clinic must compile the requested documents for the desk-based assessment and submit these within four weeks of request. These documents should be to hand for the most part and include copies of the clinic’s most recent audits, standard operating procedures, evidence of training and quality management items such as minutes from quality meetings or audit schedules etc. Clinics are also requested to complete our own audit tools.

 

Documents should be submitted in a comprehensive, easily accessible format, identifying which document relates to which Code of Practice guidance note.

 

Receiving these documents on time is critical for the inspection process, as our inspectors dedicate a significant amount of time in a carefully planned schedule to review them. Evidence provided within these documents allows the inspection team to assess a clinic’s compliance. Where they are provided late then inspectors will have little, or no opportunity to review them.

 

We know that there may occasionally be significant unforeseen circumstances which may affect the PR’s ability to submit these documents by the due date. In such situations the PR may request an extension of the due date for submission which must be communicated within good time to the inspection team. This will be considered on a case-by-case basis and where possible, we will try to accommodate such requests. It is expected that such cases are extremely rare.

 

If there is not enough time available to review late documents, the inspection team could decide that sufficient evidence has not been provided to demonstrate compliance for specific guidance notes, and a non-compliance might be cited within the inspection report for those regulatory areas not assessed.

 

Additionally, when clinics fail to submit the necessary information to the HFEA as part of the licensing process, this may result in a potential breach of Schedule 3B Paragraphs 1(1), (2) and (3) of the HFEA Act 1990 (as amended) and also is a breach of licence condition T9f. 

 

NICE draft guidance published: “Fertility problems: assessment and treatment”

Earlier this month the National Institute for Health and Care Excellence (NICE) published its draft guidance “Fertility problems: assessment and treatment”. 

 

Our statement in response is available to read here. 

 

The draft guidance is open for consultation until Tuesday 21 October at 5pm.

 

 

Did you know?

Alternate text

The inspection team would like to highlight the following professional body guidance. Please review this information and implement changes to your practice and SOPs as necessary.

 

Handling injectable medications in anaesthesia | Association of Anaesthetists

 

On page 5 of this document is a reminder that clinicians should perform the complete drawing up/labelling process for one medication at a time. Medications should not be drawn up in batches for multiple patients.

 

NHS England » Guidance on minimising time weighted exposure to nitrous oxide in healthcare settings in England

  • NHS trusts in England are advised to conduct a thorough COSHH risk assessment (Control of Substances Hazardous to Health) for each area where gas and air is administered.
  • You should ensure adequate Local Exhaust Ventilation (LEV) systems are in place to capture and remove nitrous oxide from the environment.
  • You should implement regular monitoring of nitrous oxide levels in the air to ensure they remain within safe limits.
  • You should provide staff with comprehensive training on the risks of nitrous oxide exposure and the implemented control measures.

Implementation manual WHO surgical safety checklist 2009

 

The checklist is intended as a tool for use by clinicians interested in improving the safety of their procedures.

 
TwitterFacebookE-MailInstagram

Editorial statement

Clinic Focus is the official electronic newsletter of the Human Fertilisation and Embryology Authority, is produced by the editorial team of the HFEA and provides a monthly roundup of news and information for clinics and their staff working in the field of fertility treatment.

No part of this publication may be reproduced without prior permission.

 

You can view our privacy policy on our website.

 

Click here to unsubscribe 

 

2 Redman Place

London

E20 1JQ

 

© Copyright Human Fertilisation and Embryology Authority, 2019